UPCC 31216: Phase I/II Trial of Regorafenib Hydroxychloroquine and Entinostat in Metastatic Colorectal Cancer
Enrolling By Invitation
99 years or below
All
Phase
2
44 participants needed
1 Location
Brief description of study
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Colorectal Cancer
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 827226
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
